Viridian Therapeutics Inc
1S1
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,890.80 | 74.40 | 0.84% |
| CAC 40 | 7,802.97 | 80.88 | 1.05% |
| DAX 40 | 24,226.79 | 217.41 | 0.91% |
| Dow JONES (US) | 44,254.78 | 231.49 | 0.53% |
| FTSE 100 | 8,954.73 | 28.18 | 0.32% |
| HKSE | 24,498.95 | 18.81 | -0.08% |
| NASDAQ | 20,730.49 | 52.69 | 0.25% |
| Nikkei 225 | 39,901.19 | 237.79 | 0.60% |
| NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
| S&P 500 | 6,263.70 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,639.00 | 77.20 | 0.90% |
| SSE Composite Index | 3,516.83 | 13.05 | 0.37% |